National sponsor of the Motherisk Program
Our Helplines
1-877-327-4636 Alcohol and Substance
1-800-436-8477 Morning Sickness
1-888-246-5840 HIV and HIV Treatment
1-877-439-2744 Motherisk Helpline
416-813-6780 Motherisk Helpline
Pregnancy & Breastfeeding Resources
Sept.
5
2013
St. John's,NL
2013 FACE meeting
June
23
2013
Orlando, Florida
Fetal Alcohol Canadian Expertise (FACE) Satellite Meeting
.
-
Jul192012
-
Mar292012
-
Jul282011
-
Jan272011
- Read more in our News Archive
Current Studies at Motherisk
-
Study seeks women between 4 and 12 weeks in their pregnancy with morning sickness (NVP)
-
Pregnancy in Women with Multiple Sclerosis
-
Environmental Exposures and Children's Health
-
Alcohol Use during Pregnancy
-
Control of Hypertension in Pregnancy Study
-
Folic Acid Before and During Pregnancy
-
Lamisil in Pregnancy
-
Meridia in Pregnancy
-
Autoimmune Diseases in Pregnancy Project
Anti-convulsants: Phenytoin
Motherisk Research
-
JAMA 1994 Mar 9; 271(10):767-70.
Scolnik D et al: Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. -
American Journal of Medical Genetics.68(1):18-24, 1997 Jan 10.
Nulman I, Scolnik D, Chitayat D, Farkas LD, Koren G: Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. -
Teratology, 40: 157-162, 1989.
Koren G, et al: Neuroblastoma after prenatal exposure to phenytoin: Cause and effect? -
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2146752/
Koren G: In utero exposure to phenytoin or carbamazepine. Can Fam Physicians 41: 1862-1863, 1995. -
JAMA. 1994;272(11):851. doi:10.1001/jama.1994.03520110028019
Koren G: Neurodevelopment after in utero exposure to phenytoin and carbamazepine. JAMA 272: 850-851, 1994.
![[Valid RSS]](/images/rssValid.png "Validate my RSS feed")